
Opinion|Videos|June 26, 2024
Deucravacitinib Safety Data and Treatment Selection Considerations
Bruce Strober, MD, PhD, and Linda Stein Gold, MD, provide clinical insights on long-term safety data for deucravacitinib and selecting the right treatment for the right patient.
Advertisement
0:05 Long-term Safety Data of Deucravacitinib
6:55 Selecting the Right Treatment for the Right Patient
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD
2
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
3
CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports
4
Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib
5






































































